Pancreatic Cancer Therapeutics & Diagnostics Market – Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Type (Treatment {Targeted Therapies, Chemotherapy, Surgery, Other}, Diagnostics {Imaging, Biopsy, Endoscopic Ultrasound, Other}), By End-User (Hospital & Clinic, Ambulatory Centers, Others) By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 4.72 Billion
CAGR (2026-2031)	7.56%
Fastest Growing Segment	Treatment
Largest Market	North America
Market Size (2031)	USD 7.31 Billion

Market Overview

The Global Pancreatic Cancer Therapeutics & Diagnostics Market will grow from USD 4.72 Billion in 2025 to USD 7.31 Billion by 2031 at a 7.56% CAGR. Pancreatic cancer therapeutics and diagnostics encompass pharmaceutical agents, including chemotherapies and targeted immunotherapies, alongside advanced imaging and molecular biomarker assays utilized for disease identification and staging. The market trajectory is fundamentally supported by structural drivers such as the expanding geriatric demographic and the rising global prevalence of lifestyle-related risk factors, particularly type 2 diabetes and obesity. These enduring elements necessitate intensified oncological interventions and sustain demand for management solutions, distinguishing them from transient technological trends.

However, a significant impediment to market expansion is the persistent challenge of late-stage diagnosis, which severely restricts the efficacy of available treatments and precludes curative surgical options for the majority of patients. The asymptomatic nature of the disease in its early phases leads to poor prognoses and limits the addressable patient pool for emerging therapies. According to the American Cancer Society, in 2025, the five-year relative survival rate for pancreatic cancer remained at a critically low 13 percent, highlighting the substantial clinical gaps that continue to hinder broader market success.

Key Market Drivers

The rising global incidence and prevalence of pancreatic cancer serves as the primary structural catalyst for market expansion, necessitating urgent advancements in clinical management capacity. As demographic trends shift towards an older population and lifestyle-associated risk factors such as obesity and diabetes become more ubiquitous, the volume of patients requiring oncological intervention has steadily increased. This escalating disease burden is driving demand for both diagnostic screenings and therapeutic regimens across major healthcare systems. For instance, according to the American Cancer Society, January 2025, in the 'Cancer Facts & Figures 2025' report, there were an estimated 67,440 new cases of pancreatic cancer diagnosed in the United States alone, a statistic that underscores the critical and growing need for scalable medical solutions to address this high-mortality condition.

Simultaneously, the market is being transformed by the emergence of novel immunotherapies and targeted therapeutic agents, which are shifting treatment paradigms away from conventional cytotoxic chemotherapies. Pharmaceutical pipelines are increasingly focused on precision oncology, leveraging specific biomarkers to unlock better patient outcomes in refractory cases. A notable breakthrough in this domain was highlighted when, according to Verastem Oncology, May 2025, in the 'RAMP 205 Phase 1/2 trial' update, the combination of avutometinib and defactinib achieved an 83% overall response rate in a cohort of patients with metastatic pancreatic ductal adenocarcinoma. Complementing these therapeutic strides are innovations in detection technologies; according to Targeted Oncology, May 2025, in the 'FDA Actions in Oncology' report, the regulatory body granted breakthrough device designation to the DAMO PANDA, an artificial intelligence-powered model for pancreatic cancer detection, signaling a parallel industry commitment to improving early-stage diagnosis and survival prospects.

Download Free Sample Report

Key Market Challenges

The persistent challenge of late-stage diagnosis constitutes a severe restriction on the commercial scalability of the Global Pancreatic Cancer Therapeutics & Diagnostics Market. Since the disease typically progresses without specific symptoms until metastasis, most patients are ineligible for curative surgical interventions by the time they are identified. This delay shifts the primary clinical focus from long-term disease management to short-term palliative care. Consequently, the therapeutic window is drastically compressed, preventing the sustained administration of pharmaceutical agents and reducing the total volume of drugs dispensed per patient compared to other chronic oncology indications.

This rapid clinical decline severely limits the addressable patient pool required to support high-volume market growth. The high attrition rate means that the population of eligible patients for novel therapies turns over rapidly, hindering the accumulation of a stable revenue base for developers. This trend is underscored by the narrow gap between incidence and mortality. According to the American Cancer Society, in 2025, an estimated 51,980 deaths were attributed to pancreatic cancer in the United States. This substantial mortality figure highlights the difficulty in maintaining a viable patient cohort for extended therapeutic regimens, thereby directly dampening overall market valuation.

Key Market Trends

The emergence of KRAS-targeted therapeutic agents represents a pivotal shift in treating pancreatic ductal adenocarcinoma, specifically addressing mutations previously considered undruggable. While earlier efforts focused on rare G12C mutations, recent clinical progress has successfully targeted the more prevalent G12D variant, offering new hope for refractory cases. This trend moves beyond broad-spectrum chemotherapy or indirect pathway inhibition to directly silence the oncogenic driver, establishing a precise mechanism of action for a larger subset of patients. A notable advancement in this domain was reported when, according to VJOncology, October 2025, in the 'Novel agents for KRAS G12D-mutant pancreatic cancer at ESMO 2025' report, investigational KRAS G12D inhibitors demonstrated overall response rates in the range of 30 to 50 percent in pre-treated patients. This development signifies a major leap in precision oncology, potentially establishing a new standard of care for the substantial patient population harboring this specific genetic alteration.

Simultaneously, the proliferation of liquid biopsy and blood-based biomarkers is fundamentally altering the diagnostic landscape by enabling non-invasive, early-stage detection. This trend addresses the critical need for screening tools that can identify malignancy before metastasis occurs, significantly expanding the curative window. Developers are leveraging multi-analyte assays that combine mRNA signatures with advanced algorithms to distinguish tumor signals from healthy tissue with unprecedented accuracy. Highlighting this progress, according to Mainz Biomed, October 2025, in the 'Feasibility Study of Biomarker Panel in Pancreatic Cancer Project' report, their proprietary PancAlert test achieved 100 percent sensitivity and 95 percent specificity in distinguishing pancreatic cancer patients from healthy controls. Such high-fidelity diagnostics are essential for shifting market value from palliative management to curative interventions, driving long-term growth through increased surgical eligibility and survivorship.

Segmental Insights

The Treatment segment is identified as the fastest-growing category within the Global Pancreatic Cancer Therapeutics & Diagnostics Market. This expansion is primarily driven by the increasing development and adoption of novel therapeutic modalities, including targeted therapies and immunotherapies, which address high unmet medical needs. Regulatory bodies, such as the U.S. Food and Drug Administration, have significantly contributed to this trend by granting approvals for new drug formulations and combination regimens. Furthermore, consistent investment in pharmaceutical research and development aims to improve patient outcomes, thereby fueling the continuous demand for effective therapeutic interventions globally.

Regional Insights

North America maintains a leading position in the global pancreatic cancer therapeutics and diagnostics market due to high healthcare expenditure and the significant prevalence of the disease. The dominance of the region is further supported by the presence of major pharmaceutical companies that invest heavily in research and clinical trials. Favorable regulatory frameworks provided by the U.S. Food and Drug Administration streamline the approval process for new drugs and diagnostic tools. Additionally, established reimbursement policies facilitate patient access to treatments, ensuring sustained market growth within the region.

Recent Developments

• In December 2024, Merus N.V. announced that the U.S. Food and Drug Administration granted accelerated approval for its bispecific antibody, zenocutuzumab, for the treatment of NRG1 fusion-positive pancreatic adenocarcinoma. This regulatory milestone establishes the first targeted therapy specifically indicated for this rare genetic subtype of pancreatic cancer in patients with advanced unresectable or metastatic disease. The approval was based on compelling efficacy data from the eNRGy clinical trial, which demonstrated durable objective responses. The company stated that this development underscores the importance of genomic testing and delivers a novel precision medicine option to a patient population with historically limited treatment alternatives.
• In August 2024, RenovoRx announced a key operational milestone in its pivotal Phase 3 TIGeR-PaC clinical trial with the enrollment of the first patient at the University of Nebraska Medical Center. This study evaluates the company's proprietary Trans-Arterial Micro-Perfusion therapy platform, designed to deliver chemotherapy directly to the pancreas via a specialized catheter. The investigational method aims to increase the concentration of gemcitabine in the tumor while minimizing systemic side effects compared to standard intravenous delivery. The company emphasized that adding this major clinical site would accelerate patient recruitment and help validate the platform's potential for treating locally advanced pancreatic cancer.
• In May 2024, Verastem Oncology released positive interim safety and efficacy data from its Phase 1/2 RAMP 205 clinical trial evaluating a novel combination therapy for metastatic pancreatic cancer. The study investigates the company's investigational RAF/MEK clamp combined with its FAK inhibitor and standard chemotherapy in patients with KRAS-mutated pancreatic ductal adenocarcinoma. The reported results indicated a high confirmed objective response rate among the initial patients treated, surpassing historical benchmarks for current standard-of-care treatments. The company highlighted that these findings validate its strategy of targeting the RAS/MAPK pathway to potentially overcome resistance and improve survival in this challenging indication.
• In February 2024, Ipsen announced that the U.S. Food and Drug Administration granted approval for its liposomal irinotecan injection, marketed as Onivyde, in combination with oxaliplatin, fluorouracil, and leucovorin. This regimen is now authorized as a first-line treatment for adult patients diagnosed with metastatic pancreatic adenocarcinoma. The regulatory decision was supported by results from the Phase 3 NAPOLI 3 clinical trial, which showed that the combination significantly improved overall survival compared to standard nab-paclitaxel and gemcitabine therapy. This approval represents a significant expansion of the company's oncology portfolio and provides a new therapeutic standard for patients with this aggressive disease.

Key Market Players

• Myriad Genetics Inc.
• Pfizer Inc.
• Novartis AG
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Amgen Inc.
• Viatris Inc.
• Boston Scientific Corporation
• FUJIFILM Holdings Corporation
• Canon Inc.
• Rafael Holdings Inc

By Type	By End-User	By Region
Treatment {Targeted Therapies Chemotherapy Surgery Other} Diagnostics {Imaging Biopsy Endoscopic Ultrasound Other}	Hospital & Clinic Ambulatory Centers Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Pancreatic Cancer Therapeutics & Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Pancreatic Cancer Therapeutics & Diagnostics Market, By Type:

• Treatment {Targeted Therapies
• Chemotherapy
• Surgery
• Other}
• Diagnostics {Imaging
• Biopsy
• Endoscopic Ultrasound
• Other}

• Pancreatic Cancer Therapeutics & Diagnostics Market, By End-User:

• Hospital & Clinic
• Ambulatory Centers
• Others

• Pancreatic Cancer Therapeutics & Diagnostics Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE